Journal of Hematology & Oncology
-
Publication Venue For
- Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.. 11:29. 2018
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.. 10:55. 2017
- Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.. 9:71. 2016
- Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.. 8:109. 2015
- F-BAR family proteins, emerging regulators for cell membrane dynamic changes-from structure to human diseases.. 8:47. 2015
- A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.. 6:17. 2013
- Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. 6:12-12. 2013
- Fact or fiction - identifying the elusive multiple myeloma stem cell. 6:91-91. 2013
- Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.. 6:62. 2013
- Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.. 5:15. 2012
- Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.. 3:27. 2010